I 

118TH CONGRESS 

2D SESSION H. R. 8299 

To require the Secretary of Health and Human Services, in consultation 

with the Secretary of Commerce, the Council for Technology and Innovation of the Centers for Medicare & Medicaid Services, and the Commissioner of Food and Drugs, to carry out a program to facilitate and 

coordinate efforts between the United States and Israel to expand and 

enhance collaboration on the development and delivery of health care 

products and services. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 8, 2024 

Mr. BUCHANAN (for himself, Mr. SOTO, and Mrs. MILLER-MEEKS) introduced 

the following bill; which was referred to the Committee on Energy and 

Commerce 

A BILL 

To require the Secretary of Health and Human Services, 

in consultation with the Secretary of Commerce, the 

Council for Technology and Innovation of the Centers 

for Medicare & Medicaid Services, and the Commissioner 

of Food and Drugs, to carry out a program to facilitate 

and coordinate efforts between the United States and 

Israel to expand and enhance collaboration on the development and delivery of health care products and services. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 8299 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Maximizing Israel-U.S. 

3 Research Advancement and Collaborative Leadership in 

4 Emerging Medical Technology Act of 2024’’ or the ‘‘MIR5 ACLE Medical Technology Act of 2024’’. 

6 SEC. 2. PROGRAM FOR FACILITATION AND COORDINATION 

7 OF UNITED STATES-ISRAEL EFFORTS ON THE 

8 DEVELOPMENT AND DELIVERY OF HEALTH 

9 CARE PRODUCTS AND SERVICES. 

10 (a) IN GENERAL.—Subject to the availability of ap11 propriations, the Secretary of Health and Human Serv12 ices, in consultation with the Secretary of Commerce, the 

13 Council for Technology and Innovation of the Centers for 

14 Medicare & Medicaid Services, and the Commissioner of 

15 Food and Drugs, shall carry out a program to facilitate 

16 and coordinate efforts between the United States and 

17 Israel to expand and enhance collaboration on— 

18 (1) the development of health care products and 

19 services; and 

20 (2) the delivery of such products and services to 

21 those in need. 

22 (b) PROGRAM COMPONENTS.—The program under 

23 subsection (a) shall include facilitation and coordination 

24 of efforts including each of the following: 

25 (1) RESEARCH AND DEVELOPMENT.— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 8299 IH

1 (A) Joint research projects between United 

2 States and Israeli institutions and companies. 

3 (B) Promoting collaboration in areas such 

4 as medical device technology, pharmaceuticals 

5 including biological products, genomics, and in6 novative digital health care solutions and health 

7 care systems management, including a special 

8 focus on early-stage clinical trials. 

9 (C) With respect to biological products, 

10 supporting— 

11 (i) innovation; 

12 (ii) process optimization; and 

13 (iii) the development of advanced 

14 manufacturing techniques that can en15 hance productivity, reduce costs, and im16 prove product quality. 

17 (D) Work toward developing a framework 

18 for sharing health data for research purposes 

19 with the Ministry of Health of Israel. 

20 (2) INNOVATION AND START-UP ECOSYSTEM.— 

21 (A) Fostering collaboration between United 

22 States and Israeli start-up and other companies 

23 in the health care sector. 

24 (B) Facilitating innovative technology ac25 ceptance by the marketplace. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HR 8299 IH

1 (C) Facilitating mechanisms for technology 

2 transfer and joint venture opportunities. 

3 (D) Supporting innovation hubs to accel4 erate the development and commercialization of 

5 United States health care technologies in the 

6 Israeli market, including by encouraging cyber7 security standards for sharing data, promoting 

8 patient privacy, and encouraging research. 

9 (3) REGULATORY HARMONIZATION AND INTEL10 LECTUAL PROPERTY PROTECTION.—Establishing 

11 joint efforts— 

12 (A) to ensure intellectual property protec13 tion; 

14 (B) to increase regulatory harmonization, 

15 including with respect to regulatory data pro16 tection for biological products; 

17 (C) to formulate plans for a commer18 cialization framework for medical device tech19 nologies; 

20 (D) to encourage a potential mutual rec21 ognition agreement for pharmaceutical good 

22 manufacturing Practices between the Food and 

23 Drug Administration and Israeli regulators; 

24 (E) to strengthen and reaffirm the con25 fidentiality commitment with the Food and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HR 8299 IH

1 Drug Administration and the Pharmaceutical 

2 Division, the Medical Devices Department, and 

3 the National Food Services and Nutrition Divi4 sion of the Ministry of Health of Israel; 

5 (F) to encourage Israel’s participation in 

6 regulatory harmonization and cooperation orga7 nizations; and 

8 (G) to expand international collaboration 

9 under Project Orbis for concurrent submission 

10 and review of oncology products. 

11 (4) HEALTH CARE SYSTEM STRENGTHENING.— 

12 Facilitating the sharing of best practices, knowledge, 

13 and skills in areas such as clinical care and health 

14 care management. 

15 (5) TELEMEDICINE AND DIGITAL HEALTH CO16 OPERATION.—Establishing initiatives— 

17 (A) to enhance telemedicine infrastructure; 

18 (B) to promote interoperability between 

19 United States and Israeli health care systems; 

20 and 

21 (C) to facilitate collaboration on digital 

22 health technologies, data analytics, and cyberse23 curity. 

24 (6) DISEASE PREVENTION INITIATIVES.—Col25 laborating in disease prevention, including joint efVerDate Sep 11 2014 03:55 Jun 07, 2024 Jkt 049200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H8299.IH H8299

kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HR 8299 IH

1 forts to combat infectious diseases, develop vaccines, 

2 and share epidemiological data. 

3 (7) BIOLOGICAL PRODUCT MANUFACTURING.— 

4 (A) Promoting biological product manufac5 turing. 

6 (B) Establishing joint manufacturing fa7 cilities for biological products in facilities in the 

8 United States that leverage the strengths and 

9 expertise of both countries. 

10 (C) Pursuing accelerated development of 

11 life-saving treatments and new sources of nutri12 tion that are both healthier and more available 

13 at an affordable cost. 

14 (D) Workforce training and skill develop15 ment, including promoting exchange programs 

16 and training initiatives to develop a skilled 

17 workforce in biological product manufacturing. 

18 (E) Supply chain resilience through stra19 tegic collaboration to identify and develop con20 tingency plans to mitigate biological product 

21 supply disruptions. 

22 (F) Facilitating public-private partnerships 

23 to support the development and scale-up of bio24 logical product manufacturing capabilities. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•HR 8299 IH

1 (c) UNITED STATES-ISRAEL HEALTH CARE COL2 LABORATION CENTER.—In carrying out the program 

3 under subsection (a), the Secretary of Health and Human 

4 Services may establish a joint United States-Israel Health 

5 Care Collaboration Center in the United States leveraging 

6 the experience, knowledge, and expertise of institutions of 

7 higher education, national laboratories, entities in the pri8 vate sector, and others in the development and delivery 

9 of health care products and services. 

10 (d) COMMENCEMENT OF IMPLEMENTATION.—Not 

11 later than 6 months after the date of enactment of this 

12 Act, the Secretary of Health and Human Services shall 

13 commence implementation of the program under this sec14 tion. 

15 (e) AUTHORIZATION OF APPROPRIATIONS.—To carry 

16 out this Act, there is authorized to be appropriated 

17 $8,000,000 for each of fiscal years 2025 through 2029. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB